Table 1:
Baseline demographics and disease characteristics in the intention-to-treat population
| Pembrolizumab plus chemotherapy (N=60) | Chemotherapy (N=63) | |
|---|---|---|
| Age, years | 62·5 (54–70) | 63·2 (58–70) |
| Sex | ||
| Male | 22 (37%) | 26 (41%) |
| Female | 38 (63%) | 37 (59%) |
| Ethnic origin | ||
| White | 49 (82%) | 58 (92%) |
| Asian | 5 (8%) | 5 (8%) |
| Black or African American | 4 (7%) | 0 |
| Other* | 2 (3%) | 0 |
| ECOG performance status† | ||
| 0 | 24 (40%) | 29 (46%) |
| 1 | 35 (58%) | 34 (54%) |
| Tumour histology | ||
| Adenocarcinoma | 58 (97%) | 55 (87%) |
| NSCLC not otherwise specified | 2 (3%) | 7 (11%) |
| Large cell carcinoma | 0 | 1 (2%) |
| Disease stage | ||
| IIIA | 0 | 1 (2%) |
| IIIB | 1 (2%) | 2 (3%) |
| IV | 59 (98%) | 60 (95%) |
| Smoking status | ||
| Current or former smoker | 45 (75%) | 54 (86%) |
| Never smoker | 15 (25%) | 9 (14%) |
| Stable brain metastases | 9 (15%) | 6 (10%) |
| PD-L1 TPS | ||
| <1% | 21 (35%) | 23 (37%) |
| 1–49% | 19 (32%) | 23 (37%) |
| ≥50% | 20 (33) | 17 (27%) |
| Previous systemic (neo)adjuvant therapy | 4 (7%) | 5 (8%) |
Data are median (IQR) or n (%). ECOG=Eastern Cooperative Oncology Group. NSCLC=non-small-cell lung cancer. TPS=tumour proportion score.
*
Other ethnic origins in the pembrolizumab plus chemotherapy group included one patient (2%) who was American Indian or Alaska Native and one patient (2%) who did not define their ethnic origin.
†
One patient (2%) in the pembrolizumab plus chemotherapy group had an ECOG performance status of 2; this patient did not receive study treatment.